医学と薬学　76/3　2019年3月号

出版社： 自然科学社
発行日： 2019-02-27
分野： 薬学  >  雑誌
ISSN： 03893898
雑誌名：
特集： 心臓血管疾患（I）
電子書籍版： 2019-02-27 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

1,320 円(税込)

購入する

目次

  • 特集　心臓血管疾患（I）

    序文
    冠動脈疾患（内科治療）
    冠動脈疾患（外科治療）
    弁膜症
    心不全の疫学と治療

    研究
    　疑義照会義務と実際業務のあいだに浮上した新たな問題点
    　　―全国約千店舗の保険薬局への疑義照会アンケート調査から―　
    　赤血球容積分布幅変動係数は心腎貧血症候群で上昇する　
    　健常成人に対するセロトニン活性療法の影響に関する研究
    　　―無作為化比較対照臨床試験―

    Diagnosis
    　インスリンアナログ製剤と反応しないビトロスインスリン試薬および
    　　ビトロスC-ペプチド試薬の評価
    　血球沈降現象が軽減された血清補体価測定試薬オートCH50-L「生研」II 改良品の性能評価
    　液状プロトロンビン時間測定試薬「コアグピア® PT-Liquid」の基礎的検討
    　ヒト脳性ナトリウム利尿ペプチド測定試薬「ナノピア BNP-A」の基礎的検討
    　新しいインフルエンザウイルス抗原検出（迅速診断）キット
    　　「スタットマークTM FLU スティックII」の鼻腔ぬぐい液，鼻腔吸引液および
    　　　鼻汁鼻かみ液での性能と陽性判定時間の検討

    Health Care
    　子供用オリゴ糖粉末の摂取による便通改善の評価

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【特集 心臓血管疾患 ( I ) 】

P.270 掲載の参考文献
1) McDiarmid AK, Pellicori P, Cleland JG et al : Taxonomy of segmental myocardial systolic dysfunction. Eur Heart J 38 : 942-954. 2017.
PubMed
2) Sakuma H : Magnetic resonance imaging for ischemic heart disease. J Magn Reson Imaging 26 (1) : 3-13, 2007.
PubMed
3) Sen S, Escaned J, Malik IS et al : Development and validation of a new adenosine-independent index of stenosis severity from coronary wave-intensity analysis : results of the ADVISE (ADenosine Vasodilator Independent Stenosis Evaluation) study. J Am Coll Cardiol 59 (15) : 1392-1402, 2012.
PubMed
4) 虚血性心疾患の一次予防ガイドライン (2012年改訂版), 循環器病の診断と治療に関するガイドライン (2011年度合同研究班報告), 2015.
 
5) Holman RR, Paul SK, Bethel MA et al : 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 : 1577-1589, 2008.
PubMed
6) Bain S, Druyts E, Balijepalli C et al : Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs : A Bayesian meta-analysis of survival data. Diabetes, obesity & metabolism 19 : 329-335, 2017.
 
7) Palmer SC, Mavridis D, Nicolucci A et al : Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes : A Meta-analysis. JAMA 316 : 313-324, 2016.
PubMed
8) 8. Pharmacologic Approaches to Glycemic Treatment : Standards of Medical Care in Diabetes-2018. Diabetes Care 41 : S73-s85, 2018.
PubMed
9) Cariou B, Charbonnel B, Staels B : Thiazolidinediones and PPARgamma agonists : time for a reassessment. Trends Endocrinol Metab 23 : 205-215, 2012.
PubMed
10) Rehman MB, Tudrej BV, Soustre J et al : Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes : Meta-analysis of placebo-controlled randomized clinical trials. Diabetes Metab 43 : 48-58, 2017.
PubMed
11) Zannad F, Cannon CP, Cushman WC et al : Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE : a multicentre, randomised, double-blind trial. Lancet 385 : 2067-2076, 2015.
PubMed
12) Zheng SL, Roddick AJ, Aghar-Jaffar R et al : Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes : A Systematic Review and Meta-analysis. JAMA 319 : 1580-1591, 2018.
PubMed
13) Marso SP, Daniels GH, Brown-Frandsen K et al : Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 375 : 311-322, 2016.
PubMed
14) Zinman B, Wanner C, Lachin JM et al : Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373 : 2117-2128, 2015.
PubMed
15) Ueda P, Svanstrom H, Melbye M et al : Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events : nationwide register based cohort study. BMJ 363 : k4365, 2018.
PubMed
16) Sattar N, Petrie MC, Zinman B et al : Novel Diabetes Drugs and the Cardiovascular Specialist. J Am Coll Cardiol 69 : 2646-2656, 2017.
PubMed
17) 9. Cardiovascular Disease and Risk Management. Diabetes Care 40 : S75-S87, 2017.
PubMed
18) Nakamura H, Arakawa K, Itakura H et al : Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study) : a prospective randomised controlled trial. Lancet 368 : 1155-1163, 2006.
PubMed
19) Olsson AG : Expanding options with a wider range of rosuvastatin doses. Clin Ther 28 : 1747-1763, 2006.
PubMed
20) Piepoli MF, Hoes AW, Agewall S et al : 2016 European Guidelines on cardiovascular disease prevention in clinical practice : The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 37 : 2315-2381, 2016.
 
21) Neumann FJ, Sousa-Uva M, Ahlsson A et al : 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 40 (2) : 87-165, 2019.
PubMed
22) 日本循環器学会 : 2016年循環器疾患診療実態調査報告書 (JROAD).
 
23) Schomig A, Neumann FJ, Kastrati A et al : A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334 : 1084-1089, 1996.
PubMed
24) Smits PC, Vlachojannis GJ, McFadden EP et al : Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice : The COMPARE Trial (A Trial of Everolimus-Eluting Stents and Paclitaxel Stents for Coronary Revascularization in Daily Practice). JACC Cardiovasc Interv 8 : 1157-1165, 2015.
 
25) Mohr FW, Morice MC, Kappetein AP et al : Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease : 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 381 : 629-638, 2013.
PubMed
26) Boden WE, O'Rourke RA, Teo KK et al : Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356 : 1503-1516, 2007.
 
27) De Bruyne B, Fearon WF, Pijls NH et al : Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med 371 : 1208-1217, 2014.
PubMed
28) Bech GJ, De Bruyne B, Pijls NH et al : Fractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis : a randomized trial. Circulation 103 : 2928-2934, 2001.
PubMed
P.277 掲載の参考文献
1) 梶本完, 天野篤 : 虚血性心疾患UPDATE虚血性心疾患の治療の進歩 冠動脈バイパス術revisited. 医学の歩み 259 : 723-728, 2016.
 
2) Dohi S, Kajimoto K, Miyauchi K et al : Comparing outcomes after off-pump coronary artery bypass versus drug-eluting stent in diabetic patients. J Cardiol 59 : 195-201, 2012.
PubMed
3) 虚血性心疾患に対するバイパスグラフトと手術術式の選択ガイドライン. 循環器病の診断と治療に関するガイドライン (2010年度合同研究班報告), 2012.
 
4) Tabata M, Grab JD, Khalpey Z et al : Prevalence and variability of internal mammary artery graft use in contemporary multivessel coronary artery bypass graft surgery : analysis of the Society of Thoracic Surgeons National Cardiac Database. Circulation 15 : 935-940, 2009.
 
5) Kajimoto K : Current States-of-the-art of Coronary Artery Bypass Surgery. J Jpn Coron Assoc 20 : 295-303, 2014.
 
6) Kitamura S : Physiological and metabolic effects of grafts in coronary artery bypass surgery. Circ J 75 : 766-772, 2011.
PubMed
7) Hillis LD, Smith PK, Anderson JL et al : 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J Am Coll Cardiol 58 : e123-210, 2011.
 
8) Levine GN, Bates ER, Bittl JA et al : 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines : An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery. Circulation 134 : e123-155, 2016.
 
9) Winchester DE, Wen X, Xie L et al : Evidence of pre-procedural statin therapy ; a meta-analysis of randomized trials. J Am Coll Cardiol 56 : 1099-1109, 2010.
PubMed
10) 梶本完 : 腹部大動脈瘤・末梢動脈疾患. 薬局 67 : 54-59, 2016.
 
11) 梶本完, 天野篤 : 冠動脈疾患 冠動脈バイパス術. 永井良三, 堀正二編, 循環器疾患最新の治療 2012-2013, pp.146-150, 南江堂, 東京, 2012.
 
12) Hata M, Takayama T, Sezai A et al : Efficacy of aggressive lipid controlling therapy for preventing saphenous vein graft disease. Ann Thorac Surg 88 : 1440-1444, 2009.
PubMed
13) Elgendy IY, Mahmoud A, Huo T et al : Meta-analysis of 12 trials evaluating the effects of statins on decreasing atrial fibrillation after coronary artery bypass grafting. Am J Cardiol 115 : 1523-1528, 2015.
PubMed
14) Eisen A, Cannon CP, Blazing MA et al : The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. Eur Heart J 37 : 3576-3584, 2016.
PubMed
15) Eisen A, Cannon CP, Blazing MA et al : The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. Eur Heart J 37 : 3576-3584, 2016.
PubMed
16) White CM, Caron MF, Kalus JS et al : Intravenous plus oral amiodarone, atrial septal pacing, or both strategies to prevent post-cardiothoracic surgery atrial fibrillation : the Atrial Fibrillation Suppression Trial II (AFIST II). Circulation 108 (Suppl 1) : II200-206, 2003.
 
17) 天野篤, 梶本完 : 糖尿病に合併した冠動脈疾患の治療. 糖尿病診療マスター 14 : 268-272, 2016.
 
P.288 掲載の参考文献
1) Nkomo VT, Gardin JM, Skelton TN et al : Burden of valvular heart diseases : a population-based study. Lancet 368 : 1005-1011, 2006.
PubMed
2) Coffey S, Cox B, Williams MJA : Lack of progress in valvular heart disease in the pre-transcatheter aortic valve replacement era : Increasing deaths and minimal change in mortality rate over the past three decades. Am Heart J 167 : 562-567.e2., 2014.
 
3) Masuda M, Okumura M, Doki Y et al : Thoracic and cardiovascular surgery in Japan during 2014. Japanese J Thorac Cardiovasc Surg, 2016 [Epub ahead of print]
 
4) Jabbour RJ, Dick R, Walton AS : Aortic balloon valvuloplasty?review and case series. Heart Lung Circ 17 (Suppl 4) : S73-81, 2008.
 
5) Thaden JJ, Nkomo VT, Enriquez-Sarano M : The Global Burden of Aortic Stenosis. Prog Cardiovasc Dis 56 : 565-571, 2014.
PubMed
6) Nishimura RA, Otto CM, Bonow RO et al : 2014 AHA/ACC guideline for the management of patients with valvular heart disease : A report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol 63 : e58-185, 2014.
 
7) Leon MB, Smith CR, Mack MJ et al : Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med 374 : 1609-1620, 2016.
 
8) Al-Atassi T, Thourani VH : Transcatheter aortic valve replacement in intermediate-risk patients. J Thorac Cardiovasc Surg 153 : 822-823, 2017.
PubMed
9) Nishimura RA, Otto CM, Bonow RO et al : 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 70 : 252-289, 2017.
 
10) Enriquez-Sarano M, Avierinos J-F, Messika-Zeitoun D et al : Quantitative determinants of the outcome of asymptomatic mitral regurgitation. N Engl J Med 352 : 875-883, 2005.
PubMed
11) Grigioni F, Enriquez-sarano M, Zehr KJ et al : Ischemic Mitral Regurgitation : Long-term outcome and prognostic implications with quantitative doppler assesment. Circulation 103 : 1759-1764, 2001.
 
12) Edwards NC, Moody WE, Yuan M et al : Quantification of left ventricular interstitial fibrosis in asymptomatic chronic primary degenerative mitral regurgitation. Circ Cardiovasc Imaging 7 : 946-953, 2014.
PubMed
13) Enriquez-Sarano M, Schaff HV, Orszulak TA et al : Valve Repair Improves the Outcome of Surgery for Mitral Regurgitation. Circulation 91 : 1022-1028, 1995.
PubMed
14) Dziadzko V, Clavel MA, Dziadzko M et al : Outcome and undertreatment of mitral regurgitation : a community cohort study. Lancet 391 : 960-969, 2018.
PubMed
15) Glower DD, Kar S, Trento A et al : Percutaneous mitral valve repair for mitral regurgitation in high-risk patients : Results of the EVEREST II study. J Am Coll Cardiol 64 : 172-181, 2014.
PubMed
16) Maisano F, Franzen O, Baldus S et al : Percutaneous mitral valve interventions in the real world : Early and 1-year results from the ACCESS-EU, A prospective, multicenter, nonrandomized post-approval study of the Mitraclip therapy in Europe. J Am Coll Cardiol 62 : 1052-1061, 2013.
 
17) Stone GW, Lindenfeld J, Abraham WT et al : Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med 379 : 2307-2318, 2018.
PubMed
18) Obadia J-F, Messika-Zeitoun D, Leurent G et al : Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. N Engl J Med 379 : 2297-2306, 2018.
 
19) Dujardin KS, Enriquez-Sarano M, Schaff HV et al : Mortality and morbidity of aortic regurgitation in clinical practice. A long-term follow-up study. Circulation 99 : 1851-1857, 1999.
PubMed
20) Chaliki HP, Mohty D, Avierinos J-F et al : Outcomes after aortic valve replacement in patients with severe aortic regurgitation and markedly reduced left ventricular function. Circulation 106 : 2687-2693, 2002.
PubMed
21) Masuda M, Endo S, Natsugoe S et al : Thoracic and cardiovascular surgery in Japan during 2015 : Annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 66 : 581-615, 2018.
PubMed
22) Lansac E, Centa ID, Vojacek J et al : Valve sparing root replacement : the remodeling technique with external ring annuloplasty. Ann Cardiothorac Surg 2 : 117-123, 2013.
 
23) Ozaki S, Kawase I, Yamashita H et al : Aortic valve reconstruction using self-developed aortic valve plasty system in aortic valve disease. Interact Cardiovasc Thorac Surg 12 : 550-553, 2011.
PubMed
24) Woldu B, Bloomfield GS : Rheumatic Heart Disease in the Twenty-First Century. Curr Cardiol Rep 18 : 1-11, 2016.
 
25) Tyagi G, Dang P, Pasca I et al : Progression of degenerative mitral stenosis : insights from a cohort of 254 patients. J Heart Valve Dis 23 : 707-712, 2014.
PubMed
26) Benjamin EJ, Plehn JF, D'Agostino RB et al : Mitral Annular Calcification and the Risk of Stroke in an Elderly Cohort. N Engl J Med 327 : 374-379, 1992.
 
27) Fox CS, Vasan RS, Parise H et al : Mitral annular calcification predicts cardiovascular morbidity and mortality : the Framingham Heart Study. Circulation 107 : 1492-1496, 2003.
PubMed
28) Pasca I, Dang P, Tyagi G et al : Survival in Patients with Degenerative Mitral Stenosis : Results from a Large Retrospective Cohort Study. J Am Soc Echocardiogr 29 : 461-469, 2016.
PubMed
29) Hull MC, Morris CG, Pepine CJ et al : Valvular Dysfunction and Carotid, Subclavian, and Coronary Artery Disease Treated With Radiation Therapy. Jama 290 : 2831-2837, 2003.
PubMed
30) Adabag AS, Dykoski R, Ward H et al : Critical stenosis of aortic and mitral valves after mediastinal irradiation. Catheter Cardiovasc Interv 63 : 247-250, 2004.
PubMed
31) Inoue K, Owaki T, Nakamura T et al : Clinical application of transvenous mitral commissurotomy by a new balloon catheter. J Thorac Cardiovasc Surg 87 : 394-402, 1984.
PubMed
32) Ismeno G, Renzulli A, De Feo M et al : Surgery of rheumatic mitral stenosis : Comparison of different techniques. Acta Cardiol 56 : 155-161, 2001.
PubMed
33) Topilsky Y, Maltais S, Medina Inojosa J et al : Burden of Tricuspid Regurgitation in Patients Diagnosed in the Community Setting. JACC Cardiovasc Imaging, 2018. [Epub ahead of print]
 
34) Topilsky Y, Nkomo VT, Vatury O et al : Clinical outcome of isolated tricuspid regurgitation. JACC Cardiovasc Imaging 7 : 1185-1194, 2014.
PubMed
35) Fender EA, Zack CJ, Nishimura RA : Isolated tricuspid regurgitation : outcomes and therapeutic interventions Heart 104 : 798-806, 2018.
PubMed
36) Nickenig G, Kowalski M, Hausleiter J et al : Transcatheter Treatment of Severe Tricuspid Regurgitation With the Edge-to-Edge MitraClip Technique. Circulation 135 : 1802-1814, 2017.
PubMed
37) Lurz P, Besler C, Noack T et al : Transcatheter treatment of tricuspid regurgitation using edge-to-edge repair : Procedural results, clinical implications and predictors of success. EuroIntervention 14 : e290-297, 2018.
PubMed
P.296 掲載の参考文献
1) Sato N, Kajimoto K, Keida T et al : Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry). Circ J 77 (4) : 944-951, 2013.
PubMed
2) Adams KF Jr, Fonarow GC, Emerman CL et al : Characteristics and outcomes of patients hospitalized for heart failure in the United States : rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149 (2) : 209-216, 2005.
 
3) Gheorghiade M, Abraham WT, Albert NM et al : Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296 (18) : 2217-2226, 2006.
PubMed
4) Maggioni AP, Dahlstrom U, Filippatos G et al : EURObservational Research Programme : the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 12 (10) : 1076-1084, 2010.
PubMed
5) Ambrosy AP, Fonarow GC, Butler J et al : The global health and economic burden of hospitalizations for heart failure : lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 63 (12) : 1123-1133, 2014.
PubMed
6) Shiraishi Y, Kohsaka S, Sato N et al : 9-Year Trend in the Management of Acute Heart Failure in Japan : A Report From the National Consortium of Acute Heart Failure Registries. J Am Heart Assoc 7 (18) : e008687, 2018.
PubMed
7) Pitt B, Zannad F, Remme WJ et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (10) : 709-717, 1999.
 
8) Jentzer JC, DeWald TA, Hernandez AF : Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 56 (19) : 1527-1534, 2010.
 
9) Felker GM, O'Connor CM, Braunwald E et al : Loop diuretics in acute decompensated heart failure : necessary? Evil? A necessary evil? Circ Heart Fail 2 (1) : 56-62, 2009.
PubMed
10) Cleland JG, Tendera M, Adamus J et al : The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27 (19) : 2338-2345, 2006.
 
11) McMurray JJ, Ostergren J, Swedberg K et al : Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors : the CHARM-Added trial. Lancet 362 (9386) : 767-771, 2003.
PubMed
12) Cohn JN, Tognoni G ; Valsartan Heart Failure Trial Investigators. : A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (23) : 1667-1675, 2001.
 
13) Heran BS, Musini VM, Bassett K et al : Angiotensin receptor blockers for heart failure. Cochrane Database Syst Rev : CD003040, 2012.
PubMed
14) Yusuf S, Pfeffer MA, Swedberg K et al : Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction : the CHARM-Preserved Trial. Lancet 362 (9386) : 777-781, 2003.
PubMed
15) Massie BM, Carson PE, McMurray JJ et al : Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359 (23) : 2456-2467, 2008.
PubMed
16) Flather MD, Shibata MC, Coats AJ et al : Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26 (3) : 215-225, 2005.
PubMed
17) Chatterjee S, Biondi-Zoccai G, Abbate A et al : Benefits of β blockers in patients with heart failure and reduced ejection fraction : network meta-analysis. BMJ 346 : f55, 2013.
 
18) Zannad F, McMurray JJ, Krum H et al : Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364 (1) : 11-21, 2011.
PubMed
19) Digitalis Investigation Group : The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336 (8) : 525-533, 1997.
 
20) Rathore SS, Curtis JP, Wang Y et al : Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289 (7) : 871-878, 2003.
PubMed
21) Adams KF Jr, Patterson JH, Gattis WA et al : Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial : a retrospective analysis. J Am Coll Cardiol 46 (3) : 497-504, 2005.
 
22) Hauptman PJ, McCann P, Romero JM et al : Reference Laboratory Values for Digoxin Following Publication of Digitalis Investigation Group (DIG) Trial Data. JAMA Intern Med 173 (16) : 1552-1554, 2013.
PubMed

【研究】

P.315 掲載の参考文献
1) 早瀬幸俊 : 医薬分業の問題点. YAKUGAKU ZASSHI 123 (3) : 121-132, 2003.
Medical*Online
2) 翁百合 : 医薬分業政策の評価と課題. JRIレビュー 11 (30) : 41-55, 2015.
 
3) 秋葉保次, 中村健, 西川隆他 : 医薬分業の歴史. pp.3-460, 秋葉保次, 中村健, 西川隆他編, 薬事日報社, 東京, 2012.
 
4) 鹿村恵明, 高橋淳一, 菊池幸他 : 薬局薬剤師における疑義照会の作業時間に関する調査. Jpn J Soc Pharm 31 (2) : 17-25, 2012.
 
5) 加藤隆, 池田俊也, 武藤正樹 : 薬剤師による疑義照会の評価-医療の質改善と経済的貢献の定量評価-. 日本医療・病院管理学会誌 50 (4) : 285-594, 2013.
 
6) 中居肇, 成田麻里子, 工藤香澄他 : オーダリングシステム導入に伴う疑義照会内容の把握と保険薬局からの疑義照会に対する病院薬剤師の役割. 日本病院薬剤師会雑誌 47 (7) : 863-867, 2011.
Medical*Online
7) 飯岡緒美, 大西弘高 : 医療者間コミュニケーションについて-薬剤師の立場から疑義照会場面における医師と薬剤師のコミュニケーションを考える-. 日本内科学会誌 101 (6) : 1720-1726, 2012.
 
8) 根岸悦子, 平井愛山, 吉崎昇他 : 病-診-薬連携, わかしお医療ネットワークのオンライン服薬指導システムの構築とその運用. YAKUGAKU ZASSHI 123 (3) : 191-200, 2003.
 
9) 櫻井香織, 尾崎淳子, 矢野育子他 : 病院と薬局の合意に基づく院外処せんにおける疑義照会簡素化プロトコルとその効果. 医療薬学 42 (5) : 336-342, 2016.
 
10) 渡部恵, 杉浦宗敏, 清野敏一他 : 処方オーダリングシステムにおける入力ミスの防止法とその評価-文字入力及び警告画面表示システムの有用性-. YAKUGAKU ZASSHI 122 (10) : 841-847, 2002.
 
11) 沼田稔 : "後発医薬品関連過誤" 増大への懸念-販売名を如何に分かり易く統一するか-. 医薬ジャーナル 論壇 47 (11) : 35-37, 2011.
 
12) 特集「みんなのためになる疑義照会を考えよう第1回」. PharmaTribune 9 : 23-27, 2017.
 
13) 鹿村恵明, 真野泰成, 小茂田昌代他 : 薬局薬剤師の疑義照会による医療費削減効果及び医薬分業率との関連性-全国薬局疑義照会調査-. YAKUGAKU ZASSHI 136 (9) : 1263-1273, 2016.
Medical*Online
14) 加藤隆, 中込哲, 南郷栄秀他 : 院外処方せんの疑義照会に対する評価. 日本病院薬剤師会雑誌 47 : 1194-1198, 2011.
Medical*Online
P.323 掲載の参考文献
1) Felker GM, Allen LA, Pocock SJ et al : Red cell distribution width as a novel prognostic marker in heart failure. data from the CHARM program and the Duke databank. J Am Coll Cardiol 50 : 40-47, 2007.
PubMed
2) Hsieh YP, Chang CC, Kor CT et al : The predictive role of red cell distribution width in mortality among chronic kidney disease patients. PLoS One 11 : 1-13, 2016.
PubMed
3) Silverberg D, Wexler D, Blum M et al : The cardio-renal anaemia syndrome : does it exist? Nephrol Dial Transplant 18 Suppl 8 : viii7-12, 2003.
 
4) Silverberg DS, Wexler D, Iaina A et al : The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin Nephrol 26 : 296-306, 2006.
PubMed
5) Mckee PA, Castelli WP, McNamara PM et al : The natural history of congestive heart failure : the Framingham study. N Engl J Med 285 : 1441-1446, 1971.
PubMed
6) Kanda Y : Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48 : 452-458, 2013.
PubMed
7) Jankowska EA, Haehling S, Anker SD et al : Iron deficiency and heart failure : diagnostic dilemmas and therapeutic perspectives. Eur Heart J 34 : 816-826, 2013.
 
8) Naito Y, Tsujino T, Fujimori Y et al : Impaired expression of duodenal iron transporters in Dahl salt-sensitive heart failure rats. J Hypertens 29 : 741-748, 2011.
PubMed
9) Miyamoto K, Inai K, Takeuchi D et al : Relationships among red cell distribution width, anemia, and Interleukin-6 in adult congenital heart disease. Circ J 79 : 1100-1106, 2015.
PubMed
10) Sarzynski E, Puttarajappa C, Xie Y et al : Association between proton pump inhibitor use and anemia : A retrospective cohort study. Dig Dis Sci 56 : 2349-2353, 2011.
PubMed
11) Shikata T, Sasaki N, Ueda M et al : Use of proton pump inhibitors is associated with anemia in cardiovascular outpatients. Circ J 79 : 193-200, 2015.
PubMed
12) Lazarus B, Chen Y, Wilson FP et al : Proton pump inhibitor use and risk of chronic kidney disease. JAMA Intern Med 176 : 238-246, 2016.
PubMed
13) Yepuri G, Sukhovershin R, Nazari-Shafti TZ et al : Proton pump inhibitors accelerate endothelial senescence. Circ Res 118 : e36-e42, 2016.
PubMed
P.331 掲載の参考文献
1) 健康日本 21 (休養, こころの健康), 厚生労働省.
 
2) 平成29年労働安全衛生調査 (実態調査)」, 厚生労働省.
 
3) 平成28年衛生行政報告例 (就業医療関係者), 厚生労働省.
 
4) 2017年版 リラクゼーション・温浴ビジネスの実態と展望, 矢野経済研究所.
 
5) 有田秀穂 : セロトニン欠乏脳, NHK出版, 東京, 2003.
 
6) 有田秀穂, 滝本裕之 : セロトニン神経活性化の臨床的評価 : 脳波α2成分の発現. 国際生命情報科学会誌 34 (1) : 73, 2016.
 
7) Juvia P Heuchert, Douglas M McNair : POMS 2 日本語版 マニュアル. 横山和仁監訳, 渡邊一久協力, 金子書房, 東京, 2015.
 

【Diagnosis】

P.343 掲載の参考文献
1) 石田均 : インスリンの生合成過程と化学構造. 日本臨床 55 (増刊号 3) : 79-86, 1997.
 
2) 土田温子, 矢澤麻佐子, 今井康雄他 : インスリン, プロインスリン. 日本臨牀 60 (増刊号 8) : 369-377, 2002.
 
3) 松田文子 : インスリン, C-ペプチドの測定と結果の解釈. 診断と治療 91 (9) : 1529-1532, 2003.
Medical*Online
4) 寺内康夫, 菅野信子, 粟沢元晴他 : インスリンアナログ製剤使用患者の血漿インスリン測定. 医学のあゆみ 211 (3) : 265-266, 2004.
Medical*Online
5) Kolb HJ, Standl E : Purification to homogeneity of an insulindegrading enzyme from human erythrocytes. Hoppe Seylers Z Physiol Chem 361 (7) : 1029-1039, 1980.
PubMed
6) 安藤敏子, 東真理子, 八馬慶子他 : インスリンアナログ製剤と反応しないインスリン測定試薬を用いた内因性インスリン分泌能の評価. 糖尿病 51 (1) : 39-44, 2008.
 
P.353 掲載の参考文献
1) Mayer MM : Procedure for titration of complement : Kabat EA, Mayer MM, eds. Experimental immunochemistry, Springfield, IL : Charles CThomas : 149-153, 1961.
 
2) 稲井真弥 : ヒトの補体価定量. 日本臨床 26 : 384, 1968.
Medical*Online
3) 厚生省監修 : 補体, 微生物検査必携, 免疫血清検査, 第2版. 日本公衆衛生協会 : 357, 1978.
 
4) 稲井真弥, 安田玲子 : 補体. 臨床検査 23 : 1137-1144, 1979.
 
5) 永木和義 : ClassicalおよびAlternative Pathwayを介して測定した補体の溶血活性. 臨床免疫 秋季特別増刊号 13 : 154, 1981.
 
6) 三浦隆雄 : ウィルス検査法の実際. 臨床とウィルス (別冊) 87 : 1975.
 
7) 北野悦子, 内堀恵美, 北村肇他 : 神戸常盤大学で測定依頼を受けた各種補体異常について : 測定開始後7年を経て. 補体 51 : 5, 2014.
 
8) 加藤宗, 三宅亮, 寺山孝男 : 超音波を応用した微量液の非接触攪拌技術. 日本機械学会論文集 (B編) 66 (652) : 97-102, 2000-12.
 
9) 梅村晋一郎 : 集束超音波治療. 信学FR誌 8 (3) : 168-176, 2015.
 
P.365 掲載の参考文献
1) 文部科学省, 厚生労働省 : 人を対象とする医学系研究に関する倫理指針. 平成26年12月22日 (平成29年2月28日一部改正)
 
2) 日本検査血液学会標準化委員会凝固検査標準化ワーキンググループ : 凝固検査検体取扱いに関するコンセンサス. 日本検査血液学会雑誌 17 (2) : 2016.
 
3) Lindahl AK, Abildgaard U, Staalesen R : The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. Thromb Res 64 (2) : 155-168, 1991.
PubMed
4) 積水メディカル株式会社「コアグピア(R) PT-Liquid」添付文書 第1版, 2018.
 
5) 福武勝幸 : 凝固検査の標準化の現状. プロトロンビン時間 (PT). 生物試料分析 32 (5) : 357-364, 2009.
Medical*Online
P.374 掲載の参考文献
1) 蔦本尚慶 : 斎藤能彦編, 新BNPと日常臨, p6, 南江堂, 東京, 2005.
 
2) 蔦本尚慶 : BNP, NT-proBNPの有用性. 医学のあゆみ 232 : 459-465, 2010.
Medical*Online
3) 桑原宏一郎 : 心不全バイオマーカーとしてのBNPの臨床的意義. 診断と治療 105 : 1603-1607, 2017.
Medical*Online
4) 日本心不全学会合同ガイドライン : 編集 急性・慢性心不全診療ガイドライン. pp.16-21, 2017.
 
5) 積水メディカル株式会社「ナノピア(R) BNP-A」添付文書 第2版, 2018.
 
P.385 掲載の参考文献
1) 国立感染症研究所 : インフルエンザ診断マニュアル (第3版) https://www.niid.go.jp/niid/images/lab-manual/Influenza2014.pdf
 
2) Stockton J, Ellis JS, Saville M et al : Multiplex PCR for typing and subtyping influenza and respiratory syncytial viruses. J Clin Microbiol 36 (10) : 2990-2995, 1998.
PubMed
3) Lacroix S, Vrignaud B, Avril E et al : Impact of rapid influenza diagnostic test on physician estimation of viral infection probability in paediatric emergency department during epidemic period. J Clin Virol 72 : 141-145, 2015.
PubMed
4) Ikematsu H, Kawai N, Iwaki N et al : In vitro neuraminidase inhibitory concentration (IC50) of four neuraminidase inhibitors against clinical isolates of the influenza viruses circulating in the 2010-2011 to 2014-2015 Japanese influenza seasons. J Infect Chemother 22 (9) : 599-604, 2016.
PubMed
5) 西村美香, 川上千春, 池松秀之 : 新しいインフルエンザウイルス抗原検出 (迅速診断) キット「ブライトポック(R) Flu」の基礎的検討および臨床性能評価. 医学と薬学 68 (2) : 327-336, 2012.
 
6) 高崎好生, 進藤靜生, 横山隆他 : インフルエンザ発症早期における迅速診断キット「ブライトポック(R) Flu」の診断能の検討. 医学と薬学 70 (2) : 407-413, 2013.
Medical*Online
7) 和田紀之 : インフルエンザの発症早期における迅速診断キット「アルソニック(R) Flu」の有用性. 医学と薬学 73 (12) : 1545-1550, 2016.
Medical*Online
8) 池松秀之, 池田整昭, 岩屋美奈子他 : 新しいインフルエンザウイルス抗原検出 (迅速診断) キット「ブライトポック(R) Flu・Neo」の陽性判定時間と発症早期での検出能. 医学と薬学 75 (7) : 823-832, 2018.
Medical*Online

【Health Care】

P.390 掲載の参考文献
1) 木下勝寿, 堀川麻子, 國重賢二他 : オリゴ糖粉末の摂取による便通改善の評価. 薬理と治療 45 (5) : 773-780, 2017.
Medical*Online
2) 出口ヨリ子, 牧野久美子, 岩立恵実他 : 便秘傾向の若年者のガラクトオリゴ糖含有飲料摂取による排便への影響. 日本食品新素材研究会誌 6 : 55-66, 2003.
 
3) Minamida K, Asakawa C, Sujaya IN et al : Effects of Long-Term Ingestion of Difructose Anhydride III (DFA III) on Intestinal Bacteria and Bile Acid Metabolism in Humans. J Biosci Bioeng 101 (2) : 149-156, 2006.
PubMed
4) 坂田隆, 市川宏文 : 短鎖脂肪酸の生理活性. 日本油化学会誌 46 (10) : 143-150, 1997.
 

書評

最近チェックした商品履歴

Loading...